C4 Therapeutics Shares Rise on FDA OK for CFT1946 Study
September 29 2022 - 7:56AM
Dow Jones News
By Colin Kellaher
Shares of C4 Therapeutics Inc. rose sharply in premarket trading
Thursday after the clinical-stage biopharmaceutical company
received U.S. Food and Drug Administration approval for a Phase 1/2
study of its CFT1946 protein degrader targeting BRAF-V600 mutant
solid tumors.
The Watertown, Mass., said it expects to launch the study in
cancers including lung, colorectal and melanoma by the end of the
year.
C4 said mutant BRAF-V600 accounts for about 50,000 cancer
diagnoses a year.
C4 shares, which closed Wednesday at $8.99, were recently up
7.5%, to $9.66, in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 29, 2022 07:41 ET (11:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
C4 Therapeutics (NASDAQ:CCCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
C4 Therapeutics (NASDAQ:CCCC)
Historical Stock Chart
From Sep 2023 to Sep 2024